Results 161 to 170 of about 15,392,732 (265)
Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang +11 more
wiley +1 more source
Advances and Challenges in Vaccine Development for West Nile Virus (WNV) Infection. [PDF]
Gupta A +6 more
europepmc +1 more source
Clinical intramuscular thymus transplantation yields only short‐lived efficacy and marginal therapeutic benefits. Benefiting from the spleen's intrinsic strengths—rapid vascular perfusion, abundant developmental factors, and resident progenitors—the intrasplenic thymic grafts achieve robust thymic regeneration and substantial T‐cell reconstitution ...
Shaocong Wang +10 more
wiley +1 more source
Accelerating Nipah virus vaccine development to prevent future global outbreaks. [PDF]
Ahmed Q, Shoukat SEA, Sohail F, Khan MH.
europepmc +1 more source
Development of a Malaria Vaccine [PDF]
openaire +2 more sources
A microfluidic Herd‐Immunity‐on‐a‐Chip experimentally recreates structured contact networks to quantify viral transmission dynamics. By controlling susceptible, infected, and non‐susceptible populations, the platform reveals how contact topology governs the reproduction number, outbreak propagation, herd‐immunity–like behavior, and intervention ...
Jiande Zhang +6 more
wiley +1 more source
<i>Avibacterium paragallinarum</i>: Pathogenesis Mechanisms and Subunit Vaccine Development. [PDF]
Li Z +7 more
europepmc +1 more source
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun +18 more
wiley +1 more source
Group A Streptococcal Virulence Factors and Vaccine Development-An Update. [PDF]
Fan S, Tsai CJ, Loh JMS, Proft T.
europepmc +1 more source

